Ludwig Maximilians - University of Munich
Prof. Dr. med. Dipl.-Phys. Maximilian Niyazi
Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted, but causes more toxicity. To address this, the multicentric PRIDE trial employs two cycles of bevacizumab to achieve dose escalation isotoxically. The goal is improved survival without significantly increasing side effects. The study uses a simultaneous integrated boost with a total dose of 75 Gy in 2.5 Gy per fraction.
Glioblastoma
Dose escalation of radiation dose beyond the therapeutic standard
Phase 2
Study Type : | Interventional |
Estimated Enrollment : | 146 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | A Phase IIa, Open-label, Multicenter Study of Radiochemotherapy With Isotoxic Dose Escalation and Protective VEGF Inhibition Using Bevacizumab in the Treatment of Patients With First Diagnosis of IDH Wild-type, MGMT Unmethylated Glioblastoma |
Actual Study Start Date : | April 10, 2024 |
Estimated Primary Completion Date : | April 10, 2027 |
Estimated Study Completion Date : | July 10, 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: 75 Gy with two cycles of bevacizumab |
Radiation: Dose escalation of radiation dose beyond the therapeutic standard |
Ages Eligible for Study: | 18 Years to 70 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Department of Radiation Oncology
Munich, Germany, 81377